Reports Q4 revenue $3M, consesnsus $2.56M. "We’re off to a great start in 2023, as we’ve grown covered lives from 91 million to 124 million during the last few months," said John Dobak, M.D., CEO, DermTech. "A nice mix of regional commercial and governmental payers have recognized the clinical and economic value of the DermTech Melanoma Test (DMT). We continue to have positive discussions with payers and believe a recent improvement to the DMT’s NCCN recommendation and support from patient advocacy groups will strengthen our case for coverage."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DMTK:
